Vitamin D Receptor (VDR) Gene Polymorphisms Modify the Response to Vitamin D Supplementation: A Systematic Review and Meta-Analysis

Ricardo Usategui-Martín 1,2,*, Daniel-Antonio De Luis-Román 3,4,5, José María Fernández-Gómez 6, Marta Ruiz-Mambrilla 7 and José-Luis Pérez-Castrillón 4,5,8,*

Abstract: The vitamin D receptor (VDR), a member of the nuclear receptor superfamily of transcriptional regulators, is crucial to calcitriol signalling. VDR is regulated by genetic and environmental factors and it is hypothesised that the response to vitamin D supplementation could be modulated by genetic variants in the VDR gene. The best studied polymorphisms in the VDR gene are Apal (rs7975232), BsmI (rs1544410), TaqI (rs731226) and FokI (rs10735810). We conducted a systematic review and meta-analysis to evaluate the response to vitamin D supplementation according to the BsmI, TaqI, Apal and FokI polymorphisms. We included studies that analysed the relationship between the response to vitamin D supplementation and the genotypic distribution of these polymorphisms. We included eight studies that enrolled 1038 subjects. The results showed no significant association between the TaqI polymorphism and the FF genotype of the FokI variant were associated with a better response to vitamin D supplementation (p = 0.02 and p = 0.081 and p = 0.63) and that the variant allele (Tt+tt) of the TaqI polymorphism and the FF genotype of the FokI variant were associated with a better response to vitamin D supplementation (p = 0.02 and p < 0.001). In conclusion, the TaqI and FokI polymorphisms could play a role in the modulation of the response to vitamin D supplementation, as they are associated with a better response to supplementation.

Keywords: vitamin D receptor; VDR; vitamin D; polymorphisms; TaqI; FokI; vitamin D supplementation

1. Introduction

The vitamin D receptor (VDR), a member of the nuclear receptor superfamily of transcriptional regulators, plays a crucial role in calcitriol or 1-alfa,25-dihydroxocolcalciferol (1α,25(OH)2D) signalling. VDR is activated by binding with 1α,25(OH)2D, which forms a heterodimer with the retinoid X receptor (RXR). The 1α,25(OH)2D-VDR-RXR complex migrates to the nucleus to regulate the transcription of genes involved in vitamin D effects including phosphorous and calcium metabolism, cell proliferation and the control of innate and adaptive immunity [1–3].

The VDR gene is located on chromosome 12 (12q13.11) and more than 900 allelic variants in the VDR locus have been reported. The best studied VDR gene polymorphisms are Apal (rs7975232), BsmI (rs1544410), TaqI (rs731226) and FokI (rs10735810). Apal, TaqI
and BsmI are silent genetic variants that increase mRNA stability. The FokI polymorphism is located on exon 2 and results in a protein shortened by three amino acids [4–6]. These genetic variants have been associated with a predisposition to chronic diseases such as type 2 diabetes, cancer, autoimmune diseases, cardiovascular alterations, rheumatic arthritis and metabolic bone diseases [7–10].

VDR regulation is determined by genetic and environmental factors [11]. The principal environmental factors associated with VDR regulation are diet, exposure to sunlight, infections and pollution [12–15]. It has been postulated that these environmental factors could modify vitamin D levels which regulate the receptor. The mechanism is not clearly understood but it is hypothesised that it may be through epigenetic mechanisms [16]. Other factors involved in VDR regulation are the intake of the vitamin D precursor and the production and activity of the ligand. Genetic factors could modulate the influence of environmental factors on VDR regulation [11]. In this scenario, it has been reported that the response to vitamin D supplementation differs widely between individuals and one hypothesis is that genetic variants in the VDR gene are important in the response to vitamin D supplementation. The polymorphisms in the VDR gene could modify the VDR activity and therefore could be the explanation for the different response to vitamin D supplementation [4–6,17]. Various authors have examined how genetic variants in the VDR gene are associated with the response to vitamin D supplementation, and the many genetic association studies show contradictory results [18–21]. Therefore, our objective was to conduct a systematic review and meta-analysis to evaluate the response to vitamin D supplementation according to the BsmI, TaqI, ApaI and FokI polymorphisms in the VDR gene.

2. Material and Methods

2.1. Inclusion Criteria and Search Strategy

To analyse the influence of VDR genetic variants on the response to vitamin D supplementation, studies including serum vitamin D levels before and after supplementation according to the genetic distribution of the BsmI, TaqI, ApaI and FokI VDR polymorphisms were considered eligible for inclusion.

This systematic review and meta-analysis were performed in accordance with the PRISMA guidelines [22] (Supplementary Material Table S1). We included studies evaluating the response to vitamin D supplementation according to genetic variants in the VDR gene.

To identify eligible studies, we conducted a computer-based search in the PubMed, Web of Science, Scopus and Embase electronic databases up to November 2021. Potentially relevant articles were searched for using the following terms in combination with Medical Subject Headings (MeSH) terms and text words: “Vitamin D receptor”, “VDR”, “BsmI”, “TaqI”, “ApaI”, “FokI”, “polymorphism”, “mutations”, “variants”, “cholecalciferol”, “vitamin D”, “supplementation” and “vitamin D supplementation”. No language restrictions were applied. The references of selected articles were scanned to identify additional relevant articles. The MedLine option “related articles” and review articles on the topic were also used to supplement the search.

2.2. Data Extraction

Bibliographic research and data extraction were conducted independently by three investigators (RUM, DDLR and JMFG). Differences were resolved by consensus with the senior author (JLPC). We extracted the authors names, the publication year, demographic information (age and sex), the follow-up time after vitamin D supplementation and serum vitamin D levels before and after supplementation according to the VDR gene polymorphisms.

2.3. Statistical Analysis

Independent meta-analyses were carried out to compare baseline and post-supplementation serum vitamin D levels according to the genetic distribution of the VDR polymorphisms.
included. Sub-analyses by age and sex were also carried out. Meta-analysis was only carried out when ≥3 studies were available. We analysed all polymorphisms under a dominant model for the minor alleles.

As previously described [23–25], meta-analyses were carried out using RevMan 5.0 software [26]. The difference between baseline and post-supplementation status and their 95% confidence interval (CI) were estimated for each study. Random-effects model was used to calculate the $p$-values (DerSimonian and Laird method). A $p$-value < 0.05 was considered statistically significant. To analyse the heterogeneity of the studies we applied Cochran’s Q-statistic ($p < 0.10$ indicated heterogeneity across studies). Inconsistency in the meta-analysis was estimated using the $I^2$ statistic and this represented the percentage of the observed between-study variability due to heterogeneity. The following cut-off points were applied: ($I^2 = 0–25\%$, no heterogeneity; $I^2 = 25–50\%$, moderate heterogeneity; $I^2 = 50–75\%$, large heterogeneity; $I^2 = 75–100\%$, extreme heterogeneity). To assess publication bias, Begger’s funnel plot was examined based on visual inspection. Asymmetry suggested publication bias. Finally, sensitivity analyses to examine the effect of excluding individual studies were carried out.

3. Results

3.1. Identification and Selection of Relevant Studies

Figure 1 shows the flow chart of the studies selected for inclusion in the meta-analysis. We initially identified 215 candidate articles for inclusion. After removing duplicates, the abstracts of 131 articles were reviewed and 103 were excluded. Thus, a total of 28 full text studies were assessed for eligibility. Of these, 20 articles were excluded because they did not contain the necessary information to carry out the meta-analysis (Supplementary Material Table S2). Therefore, eight studies that fulfilled the inclusion criteria were finally included in the meta-analysis [20,27–33]. The response to vitamin D supplementation according to the BsmI polymorphism in the $VDR$ gene was analysed in six studies [20,27–30,32]. Five studies statistically associated the variant genotype with response to vitamin D supplementation [27–30,32]. Two studies associated the genotypic distribution of ApaI polymorphism with the response to supplementation [29,32]. For the FokI polymorphism, four articles showed association with response to vitamin D supplementation [27,30,31,33]. All studies used genomic DNA extracted from nucleated peripheral blood cells, and genotyping was performed using polymerase chain reaction-restriction fragment (PCR-RFLP).

### Table 1.

| Authors, Year | N | Age [Years (SD)] | Gender [n (%)] | Country | Vitamin D Dose | Follow-Up Time |
|---------------|---|------------------|----------------|---------|----------------|---------------|
| Graafmans et al., 1997 | 81 | 78 (5) | 81 (100%) 0 (0%) | Netherlands | 400 IU/24 h | 12 months |

Figure 1. Flow chart of the studies selected for inclusion in the meta-analysis.
3.2. Study Characteristics

The studies included in the meta-analysis enrolled 1038 subjects. Detailed demographic characteristics are shown in Table 1. The mean age of the subjects included was 36.1 (10.2) years with a range of 10 to 78 years. Two studies included subjects aged <18 years [28,33] and one study only specified that subjects were aged >18 years [27]. There was a higher prevalence of women than men (77.8% vs. 8.6%). One article did not report the sex of the subjects [31]. The mean follow-up time after vitamin D supplementation was 7.4 (4.9) months. Baseline and post-supplementation serum vitamin D levels according to the BsmI, TaqI, ApaI and FokI polymorphisms in the VDR gene are summarized in Table 2. In the case of BsmI polymorphism, two studies associated the variant genotype with better response to vitamin D supplementation [27,30], two studies with worse response [20,32] and two studies did not show statistically significant association [28,29]. Five studies statistically associated the variant genotype of TaqI polymorphism with response to vitamin D supplementation [27–30,32]. Two studies associated the genotypic distribution of ApaI polymorphism with the response to supplementation [29,32]. For the FokI polymorphism, four articles showed association with response to vitamin D supplementation [27,30,31,33]. All studies used genomic DNA extracted from nucleated peripheral blood cells, and genotyping was performed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).

Table 1. Characteristics of the studies included in the meta-analysis.

| Authors, Year              | N  | Age [Years (SD)] | Gender [n (%)] | Country | Vitamin D Dose | Follow-Up Time |
|----------------------------|----|------------------|----------------|---------|----------------|----------------|
| Graafmans et al., 1997     | 81 | 78 (5)           | 81 (100%)      | Netherlands | 400 IU/24 h    | 12 months      |
| Arabi et al., 2009         | 167| 10 to 17         | 167 (100%)     | Lebanon  | 1100 IU/24 h   | 12 months      |
| Neyestani et al., 2013     | 140| 29 to 67         | -              | Iran     | 1000 IU/24 h   | 3 months       |
| Sanwalka et al., 2015      | 102| 11.2 (0.5)       | 102 (100%)     | India    | 333 IU/24 h    | 12 months      |
| Al-Daghri et al., 2017     | 199| >18              | 114 (57.2%)    | Saudi Arabia | 2000 IU/24 h | 12 months      |
| Mohseni et al., 2018       | 26 | 47.7 (8.0)       | 26 (100%)      | Iran     | 7000 IU/24 h   | 2 months       |
| Perez-Alonso et al., 2019  | 142| 55 (4)           | 142 (100%)     | Spain    | 800 IU/24 h    | 3 months       |
| Kazemian et al., 2020      | 176| 48.6 (8.7)       | 176 (100%)     | Iran     | 4000 IU/24 h   | 3 months       |

SD: standard deviation, IU: international units.

3.3. Meta-Analysis of the Association between Gene Variants in the VDR Gene and the Response to Vitamin D Supplementation

The results of the meta-analysis are shown in Figure 2. The results showed that the BsmI genetic variant was not significantly associated with the response to vitamin D supplementation ($p = 0.81$, Figure 2A). In the case of the TaqI polymorphism, the variant allele (Tt+tt genotype) was significantly associated with a better response to vitamin D supplementation ($p = 0.02$, Figure 2B). There was no significant association between the Apal variant and the response to vitamin D supplementation ($p = 0.63$, Figure 2C). Finally, subjects carrying the FF genotype of the FokI polymorphism in the VDR gene responded better to vitamin D supplementation than subjects with the variant allele (Ff+ff) ($p < 0.001$, Figure 2D).

When a meta-analysis includes fewer than 10 articles, the power of the test for funnel plot asymmetry is too low to distinguish the probability of real asymmetry [34]. Even so, we examined publication bias by visual inspection using Begger’s funnel plot (Supplementary Material Figure S1) and it appeared to be symmetrical, although there was some uncertainty regarding the degree of symmetry.

The results were not modified by excluding articles that included only subjects aged <18 years or only analysing articles including females. Sub-analyses on the basis
of ethnicity could not be carried out because the selected articles did not include this information. After sensitivity analysis, the exclusion of individual studies did not alter the results.

Table 2. Baseline and post-supplementation vitamin D levels according to the BsmI, TaqI, ApaI and FokI polymorphisms in the vitamin D receptor (VDR) gene.

| Authors, Year | Vitamin D Levels BEFORE Supplementation, ng/mL [Mean (SD)] | Vitamin D Levels AFTER Supplementation, ng/mL [Mean (SD)] |
|---------------|----------------------------------------------------------|----------------------------------------------------------|
| BsmI (rs1544410) | Bs, dd | TT | Tt+tt | AA | Aa+aa | FF | Ff+ff | BsmI (rs1544410) | Bs, dd | TT | Tt+tt | AA | Aa+aa | FF | Ff+ff |
| Graafmans et al., 1997 | 26 | 29 | 2 | - | - | - | - | 30.1 | 25 | 7.5 | - | - | - | - |
| Arabi et al., 2009 | 14.3 | 14.25 | 14.0 | 13.9 | - | - | - | 27.64 | 26.11 | 23.39 | 29.64 | - | - | - | - |
| Nevestani et al., 2013 | - | - | - | - | - | - | - | 38.1 | 37.9 | - | - | - | - |
| Sanwalka et al., 2015 | - | - | - | - | - | - | - | 27.77 | 22.8 | - | - | - | - |
| Al-Daghri et al., 2017 | 31.1 | 34 | 31.9 | 33.8 | 35.1 | 33.3 | 33 | 34.8 | 50.1 | 55.6 | 51.2 | 55.4 | 56.2 | 54 | 57.4 | 47.9 |
| Moloseni et al., 2018 | 9.0 | 12.75 | 16.5 | 12.2 | 13.6 | 13.9 | 13.0 | 11.2 | 11.0 | 16.7 | 11.5 | 14.6 | 14.8 | 14.6 | 28.0 | 15.3 |
| Pérez-Alonso et al., 2019 | 21 | 24.5 | 25 | 23 | 23 | 24 | 28 | 28 | 30.5 | 31 | 30 | 9 | 31.1 | - | - |
| Kazemian et al., 2020 | 30.2 | 41.7 | 31.8 | 37.4 | 40.9 | 31.35 | 34.4 | 30.8 | 99.3 | 131.2 | 105.3 | 118.9 | 111 | 98.3 | 114.9 | 107.8 |

SD: standard deviation.

Figure 2. Cont.
could modulate the response to vitamin D supplementation. Our results showed that carrying the variant allele of the TaqI polymorphism was associated with a better response to vitamin D supplementation. (B) Association between the FokI polymorphism and the response to vitamin D supplementation. Test for overall effect: $Z = 2.30$ ($p = 0.02$). Test for heterogeneity: $\chi^2 = 19.47$ ($p < 0.001$), $I^2 = 10\%$. (C) Association between the ApaI polymorphism and the response to vitamin D supplementation. Test for overall effect: $Z = 0.48$ ($p = 0.63$). Test for heterogeneity: $\chi^2 = 1.24$ ($p = 0.004$), $I^2 = 7.7\%$. (D) Association between the FokI polymorphism and the response to vitamin D supplementation. Test for overall effect: $Z = 9.39$ ($p < 0.001$). Test for heterogeneity: $\chi^2 = 2.47$ ($p = 0.04$), $I^2 = 5.9\%$.  

4. Discussion

The relationship between genetic variants in the VDR gene and the response to vitamin D supplementation remains unclear. Thus, we carried out a systematic review and meta-analysis to evaluate the response to supplementation according to the genotype distribution of the BsmI, TaqI, ApaI and FokI polymorphisms in the VDR gene. The results showed that the variant allele of the TaqI polymorphism and the FF genotype of the FokI variant were associated with a better response to vitamin D supplementation. The BsmI and ApaI polymorphisms were not associated with the response to vitamin D supplementation.

Calcitriol signalling is crucial in bone metabolism as it is involved in calcium absorption, parathormone secretion and, therefore, bone resorption and cellular differentiation. Vitamin D deficiency has been associated with bone metabolism alterations [35–37]. Therefore, vitamin D intake as a preventive nutritional treatment of osteoporosis plays an important role in improving health status [38,39], but the efficacy of supplementation varies widely between subjects [18–20]. One explanatory hypothesis is that genetic variants in VDR could modulate the response to vitamin D supplementation. Our results showed that carrying the variant allele of the TaqI polymorphism was associated with a better response to vitamin D supplementation. TaqI is a silent polymorphism located in the 3′ VDR gene region and has been associated with an increase in mRNA stability [4–6]. A previous meta-analysis associated the TaqI genetic variant with the risk of bone fracture [10]. This may be in line with our results, as the TaqI polymorphism may modify the response to vitamin D supplementation and thus could modify the risk of bone fracture. However, other factors besides vitamin D levels are involved in the susceptibility to bone fracture [40]. Our meta-analysis also associated the FF genotype of the FokI polymorphism with a better response to vitamin D supplementation. The FokI polymorphism is located on exon 2 and the F allele has been associated with the translation of a more active protein [17]. The greater activity of VDR could be associated with a better response to vitamin D supplementation. In addition, the F allele of the FokI genetic variant has also been associated with better calcium absorption, higher bone mineral density and a reduced risk of vertebral bone fractures [41–44]. Therefore, it seems clear that the F allele of the FokI polymorphism is associated with greater VDR activity, improving the response to vitamin D and calcium supplementation and being associated with the risk of bone fracture. Finally, we also performed sub analysis by age and sex due to it having been reported that vitamin D metabolism is affected by these factors [45,46]. Our results were not modified when analysing according to age and gender. In this sense, we hypothesise that differences in
vitamin D absorption caused by sex and age are probably more notable in subjects with the same genotype, and as our sample is very heterogeneous we do not observe differences.

This study had some limitations. Firstly, a general limitation of meta-analyses of genetic association studies—contradictory results and heterogeneity in the studies included—is quite common and reflects the true genetic heterogeneity of the different samples or hidden stratification of the population. Only a small number of studies were eligible for inclusion in our study and there was a lack of information in some, so they could not be included in the meta-analysis. Furthermore, several of the studies had low sample sizes with wide variations. Finally, the exposure to sunlight is one of the environmental factors which is crucial in VDR regulation [11]. Thus, it could have been interesting to analyse the results obtained as a function of sunlight exposure, but this could not be done because only one included paper reported this information [32]. Even with these limitations, this meta-analysis contributes significantly to our understanding the crucial role of VDR gene polymorphisms in the modulation of the vitamin D supplementation response.

5. Conclusions

In conclusion, this meta-analysis advances our current understanding of how VDR gene polymorphisms influence the response to vitamin D supplementation, providing moderate evidence that the variant allele of the TaqI polymorphism and the FF genotype of the FokI genetic variant were associated with a better response to vitamin D supplementation. Further research with a homogeneous design should be carried out to improve understanding of the role of VDR gene polymorphisms in the modulation of the response to vitamin D supplementation, and its possible clinical value.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/nu14020360/s1, Figure S1: Funnel plot of studies included in the meta-analysis assessing the association of genetic variants in the vitamin D receptor (VDR) gene and the response to vitamin D supplementation. (A) BsmI polymorphism. (B) TaqI polymorphism. (C) ApaI polymorphism. (D) FokI polymorphism; Table S1: PRISMA checklist; Table S2: Reasons for exclusion the articles not included in the meta-analysis.

Author Contributions: Conceptualization: J.-L.P.-C.; methodology: R.U.-M., D.-A.D.L.-R., J.M.F.-G., M.R.-M. and J.-L.P.-C.; formal analysis: R.U.-M.; investigation: R.U.-M., D.-A.D.L.-R., J.M.F.-G., M.R.-M. and J.-L.P.-C.; data curation: R.U.-M., D.-A.D.L.-R., J.M.F.-G. and J.-L.P.-C.; writing—original draft preparation: R.U.-M.; writing—review and editing: R.U.-M., D.-A.D.L.-R., J.M.F.-G., M.R.-M. and J.-L.P.-C.; supervision: J.-L.P.-C. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: All data and results are available in this manuscript.

Acknowledgments: The authors thank the participants and researchers of the primary studies identified for this meta-analysis.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Long, M.D.; Sucheston-Campbell, L.E.; Campbell, M.J.; Vitamin, D. receptor and RXR in the post-genomic era. *J. Cell Physiol.* 2015, 230, 758–766. [CrossRef]
2. Haussler, M.R.; Whitfield, G.K.; Kaneko, I.; Haussler, C.A.; Hsieh, D.; Hsieh, J.-C.; Jurutka, P.W. Molecular Mechanisms of Vitamin D Action. *Calcif. Tissue Int.* 2013, 92, 77–98. [CrossRef]
3. Reschly, E.J.; Krasowski, M.D. Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds. *Curr. Drug Metab.* 2006, 7, 349–365. [CrossRef]
4. Uitterlinden, A.G.; Fang, Y.; Van Meurs, J.B.J.; Pols, H.A.P.; Van Leeuwen, J.P.T.M. Genetics and biology of vitamin D receptor polymorphisms. *Gene* 2004, 338, 143–156. [CrossRef] [PubMed]
5. Whitfield, G.K.; Remus, L.S.; Jurutka, P.W.; Zitter, H.; Oza, A.K.; Dang, H.T.L.; Haussler, C.A.; Galligan, M.A.; Thatcher, M.L.; Dominguez, C.E.; et al. Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. *Mol. Cell. Endocrinol.* 2001, 177, 145–159. [CrossRef]

6. Barger-Lux, M.J.; Heaney, R.P.; Hayes, J.; DeLuca, H.F.; Johnson, M.L.; Gong, G. Vitamin D receptor gene polymorphism, bone mass, body size, and vitamin D receptor density. *Calcif. Tissue Int.* 1995, 57, 161–162. [CrossRef]

7. Li, L.; Wu, B.; Liu, J.-Y.; Yang, L.-B. Vitamin D receptor gene polymorphisms and type 2 diabetes: A meta-analysis. *Arch. Med. Res.* 2013, 44, 235–241. [CrossRef] [PubMed]

8. Lee, Y.H.; Bae, S.-C.; Choi, S.J.; Ji, J.D.; Song, G.G. Associations between vitamin D receptor polymorphisms and susceptibility to rheumatoid arthritis and systemic lupus erythematosus: A meta-analysis. *Mol. Biol. Rep.* 2011, 38, 3643–3651. [CrossRef]

9. Ortlepp, J.R.; Krantz, C.; Kimmel, M.; Von Korff, A.; Vesper, K.; Schmitz, F.; Mevissen, V.; Janssens, U.; Franke, A.; Hanrath, P. Additive effects of the chemokine receptor 2, vitamin D receptor, interleukin-6 polymorphisms and cardiovascular risk factors on the prevalence of myocardial infarction in patients below 65 years. *Int. J. Cardiol.* 2005, 105, 99–95. [CrossRef] [PubMed]

10. Ji, G.-R.; Yao, M.; Sun, C.-Y.; Li, Z.-H.; Han, Z. BsmI, TaqI, ApaI and FokI polymorphisms in the vitamin D receptor (VDR) gene and risk of fracture in Caucasians: A meta-analysis. *Bone* 2010, 47, 681–686. [CrossRef]

11. Saccone, D.; Asani, F.; Bormann, L. Regulation of the vitamin D receptor gene by environment, genetics and epigenetics. *Gene* 2015, 561, 171–180. [CrossRef] [PubMed]

12. Lamberg-Allardt, C. Vitamin D in foods and as supplements. *Prog. Biophys. Mol. Biol.* 2006, 92, 33–38. [CrossRef]

13. Holick, M.F. Vitamin D: A millenium perspective. *J. Cell. Biochem.* 2003, 88, 296–307. [CrossRef]

14. Agarwal, K.S.; Mughal, M.Z.; Upadhyay, P.; Berry, J.L.; Mawer, E.B.; Pileyl, J.M. The impact of atmospheric pollution on vitamin D status of infants and toddlers in Delhi, India. *Arch. Dis. Child.* 2002, 87, 111–113. [CrossRef] [PubMed]

15. Liu, P.T.; Stenger, S.; Li, H.; Wenzel, L.; Tan, B.H.; Krutzik, S.R.; Ochoa, M.T.; Schauber, J.; Wu, K.; Meinken, C. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. *Science* 2006, 311, 1770–1773. [CrossRef]

16. Fetahu, I.S.; Hobaus, J.; Kallay, E. Vitamin D and the epigenome. *Front. Physiol.* 2014, 5, 164. [CrossRef] [PubMed]

17. Arai, H.; Miyamoto, K.; Taketani, Y.; Yamamoto, H.; Iemori, Y.; Franke, A.; Hanrath, P. Additive effects of the chemokine receptor 2, vitamin D receptor, interleukin-6 polymorphisms and cardiovascular risk factors on the prevalence of myocardial infarction in patients below 65 years. *Int. J. Cardiol.* 2005, 105, 99–95. [CrossRef] [PubMed]

18. Barry, E.L.; Rees, J.R.; Peacock, J.L.; Tott, A.; Lewis, G.; Ahnen, D.J.; Resnic, R.S.; Burke, C.A.; et al. Genetic variants in CYP2R1, CYP24A1 and VDR modify the efficacy of vitamin D3 supplementation for increasing serum 25-hydroxyvitamin D levels in a randomized controlled trial. *J. Clin. Endocrinol. Metab.* 2014, 99, E2133–E2137. [CrossRef]

19. Lee, Y.H.; Bae, S.-C.; Choi, S.J.; Ji, J.D.; Song, G.G. Associations between vitamin D receptor polymorphisms and susceptibility to rheumatoid arthritis and systemic lupus erythematosus: A meta-analysis. *Mol. Biol. Rep.* 2011, 38, 3643–3651. [CrossRef]

20. Graafmans, W.C.; Lips, P.; Ooms, M.E.; Van Leeuwen, J.P.; Pols, H.A.; Uitterlinden, A.G. The effect of vitamin D supplementation. *Eur. J. Cancer Prev.* 2001, 10, 57–60. [CrossRef] [PubMed]

21. Ghodoosi, N.; Zarins, K.R.; et al. Effect of vitamin D receptor polymorphisms on plasma oxidative stress and apoptotic biomarkers in healthy women. *Mol. Cell. Endocrinol.* 2009, 301, 110–116. [CrossRef] [PubMed]

22. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; Group, T.P. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med.* 2009, 6, e1000097. [CrossRef] [PubMed]

23. Okada, S.; Yoshi, Y.; Nishida, Y.; Hozumi, Y.; Arima, K.; Fujita, S.; et al. The association between genetic variants in CYP2E1 and CTRC genes and susceptibility to alcoholic pancreatitis: A systematic review and meta-analysis. *Genes Nutr.* 2013, 8, 561–569. [CrossRef] [PubMed]

24. Abu-Iruda, N.; Haggag, A.; El-Omairy, H.; El-Sherbini, A.; Yassin, M.; Moustafa, A. Vitamin D receptor BsmI polymorphism modulates soy intake and 25-hydroxyvitamin D supplementation benefits in cardiovascular disease risk factors profile. *Genes Nutr.* 2013, 8, 561–569. [CrossRef] [PubMed]

25. Albarran-Pinto, J.; Ibarra, E.; Martínez-Pintado, P.; et al. Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. *Science* 2014, 343, 1710–1714. [CrossRef] [PubMed]

26. Review Manager (RevMan) [Computer Program]; Version 5.3; The Nordic Cochrane Centre, The Cochrane Collaboration: Copenhagen, UK, 2014.
30. Mohseni, H.; Amani, R.; Hosseini, S.A.; Ekrami, A.; Ahmadzadeh, A.; Latifi, S.M. Genetic Variations in VDR could Modulate the Efficacy of Vitamin D3 Supplementation on Inflammatory Markers and Total Antioxidant Capacity among Breast Cancer Women: A Randomized Double Blind Controlled Trial. *Asian Pac. J. Cancer Prev.* **2019**, *20*, 2065–2072. [CrossRef] [PubMed]

31. Neyestani, T.R.; Djazayery, A.; Shab-Bidar, S.; Eshraghian, M.R.; Kalayi, A.; Shariatzadeh, N.; Khalaji, N.; Zahedirad, M.; Gharavi, A.; Housshiarrad, A.; et al. Vitamin D Receptor Fok-I polymorphism modulates diabetic host response to vitamin D intake: Need for a nutrigenetic approach. *Diabetes Care.* **2013**, *36*, 550–556. [CrossRef]

32. Pérez-Alonso, M.; Briongos, L.-S.; Ruiz-Mambrilla, M.; Velasco, E.A.; Olmos, J.M.; De Luis, D.; Dueñas-Laítia, A.; Pérez-Castrillón, J.-L. Association Between Bat Vitamin D Receptor 3′ Haplotypes and Vitamin D Levels at Baseline and a Lower Response After Increased Vitamin D Supplementation and Exposure to Sunlight. *Int. J. Vitam. Nutr. Res.* **2020**, *90*, 290–294. [CrossRef]

33. Sanwalka, N.; Khadilkar, A.; Chiplonkar, S.; Khatod, K.; Phadke, N.; Khadilkar, V. Influence of Vitamin D Receptor Gene Fok1 Polymorphism on Bone Mass Accrual Post Calcium and Vitamin D Supplementation. *Indian J. Pediatr.* **2015**, *82*, 985–990. [CrossRef]

34. Cochrane Handbook for Systematic Reviews of Interventions. Available online: http://handbook-5-1.cochrane.org (accessed on 21 November 2021).

35. De Martinis, M.; Allegra, A.; Sirufo, M.M.; Tonacci, A.; Pioggia, G.; Raggiunti, M.; Ginaldi, L.; Gangemi, S. Vitamin D Deficiency, Osteoporosis and Effect on Autoimmune Diseases and Hematopoiesis: A Review. *Int. J. Mol. Sci.* **2021**, *22*, 8855. [CrossRef] [PubMed]

36. Priemel, M.; Von Domarus, C.; Klatte, T.O.; Kessler, S.; Schlie, J.; Meier, S.; Proksch, N.; Pastor, F.; Netter, C.; Streichert, T.; et al. Bone mineralization defects and vitamin D deficiency: Histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. *J. Bone Miner. Res.* **2010**, *25*, 305–312. [CrossRef] [PubMed]

37. Binkley, N. Does Low Vitamin D Status Contribute to “Age-Related” Morbidity? *J. Bone Miner. Res.* **2007**, *22*, V55–V58. [CrossRef]

38. Tang, B.M.P.; Eslick, G.D.; Nowson, C.; Smith, C.; Bensoussan, A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: A meta-analysis. *Lancet* **2007**, *370*, 657–666.

39. Chevalley, T.; Rizzoli, R.; Nydegger, V.; Slosman, D.; Rapin, C.H.; Michel, J.P.; Vasey, H.; Bonjour, J.P. Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-D-replete elderly patients. *Osteoporos. Int.* **1994**, *4*, 245–252. [CrossRef]

40. Boonen, S.; Lips, P.; Bouillon, R.; Bischoff-Ferrari, H.A.; Vanderschueren, D.; Haentjens, P. Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: Evidence from a comparative metaanalysis of randomized controlled trials. *J. Clin. Endocrinol. Metab.* **2007**, *92*, 1415–1423. [CrossRef]

41. Moradi, S.; Khorrami-Nezhad, L.; Maghbbooli, Z.; Hosseini, B.; Keshavarz, S.A.; Mirzaei, K. Vitamin D Receptor Gene Variation, Dietary Intake and Bone Mineral Density in Obese Women: A Cross Sectional Study. *J. Nutr. Sci. Vitaminol.* **2017**, *63*, 228–236. [CrossRef]

42. Abrams, S.A.; Griffin, I.J.; Hawthorne, K.M.; Chen, Z.; Gunn, S.K.; Wilde, M.; Darlington, G.; Shyapalo, R.J.; Ellis, K.J. Vitamin D receptor Fok1 polymorphisms affect calcium absorption, kinetics, and bone mineralization rates during puberty. *J. Bone Miner. Res.* **2005**, *20*, 945–953. [CrossRef]

43. Ames, S.K.; Ellis, K.J.; Gunn, S.K.; Copeland, K.C.; Abrams, S.A. Vitamin D receptor gene Fok1 polymorphism predicts calcium absorption and bone mineral density in children. *J. Bone Miner. Res.* **1999**, *14*, 740–746. [CrossRef]

44. Moffett, S.P.; Zmuda, J.M.; Cauley, J.A.; Ensrud, K.; Ahillier, T.; Hochberg, M.C.; Li, J.; Cayabyab, S.; Lee, J.M.; Peltz, G.; et al. Association of the VDR Translation Start Site Polymorphism and Fracture Risk in Older Women. *J. Bone Miner. Res.* **2007**, *22*, 730–736. [CrossRef] [PubMed]

45. Gallagher, J.C. Vitamin D and Aging. *Endocrinol. Metab. Clin. N. Am.* **2013**, *42*, 319–332. [CrossRef] [PubMed]

46. Verdoia, M.; Schaffer, A.; Barbieri, L.; Di Giovine, G.; Marino, P.; Suryaprana, H.; De Luca, G. Impact of gender difference on vitamin D status and its relationship with the extent of coronary artery disease. *Nutr. Metab. Cardiovasc. Dis.* **2015**, *25*, 464–470. [CrossRef] [PubMed]